- |||||||||| Retrospective data, Journal: Double Povidone-Iodine 5% Preparation Before Cataract Surgery for Endophthalmitis Prevention. (Pubmed Central) - Mar 25, 2025
The iStent infinite group also had clinically relevant and statistically significantly superior reduction from baseline in unmedicated MDIOP without surgical complications compared to Hydrus. A double povidone-iodine preparation may provide more robust prophylaxis against postcataract extraction endophthalmitis than a single preparation.
- |||||||||| nitroprusside / Generic mfg.
Journal: Unlocking the Untapped Potential of Photoresponsive Dual-Gas Nanomedicine in Glaucoma Therapy. (Pubmed Central) - Mar 24, 2025 activates the AKT/p-AKT/eNOS/sGC signaling pathway, while NO binds to soluble guanylate cyclase (sGC), converting guanosine triphosphate (GTP) to cyclic guanosine monophosphate (cGMP), relaxing trabecular meshwork cells and enhancing aqueous humor outflow. This dual-gas system demonstrates high therapeutic efficacy in lowering IOP and offers a mechanistic advancement in glaucoma treatment through synergistic gas therapy.
- |||||||||| Review, Journal: Virtual Reality Visual Field Testing in Glaucoma: Benefits and Drawbacks. (Pubmed Central) - Mar 24, 2025
VRVFT presents several benefits, making it a promising alternative or complement to conventional glaucomatous visual field testing in outpatient clinics and remote settings. Addressing technical limitations and standardizing protocols are essential for broader clinical adoption.
- |||||||||| Journal: Patient-Reported Burden of Illness and Unmet Needs in Demodex blepharitis. (Pubmed Central) - Mar 24, 2025
This suggested that the effectiveness of the reported symptom management options was temporary and highlighted an unmet need in treating the root cause of the disease. Patients with Demodex blepharitis were symptomatic, and the commonly used management options for Demodex blepharitis lacked long-term symptom relief or mite eradication, demonstrating a high unmet need in treating patients with Demodex blepharitis.
- |||||||||| mitomycin / Generic mfg.
Journal: Comparing the outcome of delayed postoperative versus intraoperative mitomycin C use in trabeculectomy: A randomized control trial. (Pubmed Central) - Mar 24, 2025 There were higher incidences of hypotony (41.9% vs 36%) in Group I. Incidences of persistent-hypotony (p?=?0.032) and late-hypotony (p?=?0.127) were higher in Group I. Two eyes developed hypotony maculopathy in Group I, while none in Group II. The blebs in Group I were more avascular, cystic and developed thinning, while those in Group II were diffuse and shallow.ConclusionsDelayed postoperative MMC application may be as effective as standard trabeculectomy with MMC in lowering IOP with a lower rate of complications.
- |||||||||| Journal: Enhancing safety of transscleral diode cyclophotocoagulation: Check the tip before use. (Pubmed Central) - Mar 24, 2025
During the procedure, he developed a scleral burn attributed to pigment on the laser probe tip. The burn healed spontaneously with topical treatment alone, highlighting the potential for scleral tissue to heal remarkably without further surgical intervention.ConclusionThis case report underscores the importance of vigilance during TDLC procedures and careful management of potential pigment sources to prevent scleral damage.
- |||||||||| Glanatec (ripasudil) / Kowa, amiodarone / Generic mfg., Rhopressa (netarsudil) / Alcon
Journal: Ripasudil does not induce phospholipid accumulation in human corneal epithelial cells. (Pubmed Central) - Mar 23, 2025 Unlike systemic amiodarone and antimalarials, topical agents do not typically induce the development of this corneal condition...In contrast, ripasudil and Y-27632 lack these structural features. Our results suggest that ripasudil has a low likelihood of inducing cornea verticillata.
- |||||||||| Journal: Maculopathy due to hypotony: A diagnostic challenge. (Pubmed Central) - Mar 23, 2025
Given the patient's history of diabetes mellitus, it was initially diagnosed as diabetic macular edema (DME), which delayed appropriate treatment. This led to worsening corneal decompensation, ultimately requiring a corneal transplant in the form of Descemet membrane endothelial keratoplasty (DMEK).
- |||||||||| Journal, Surgery: Evidence-based Guidelines for Keratorefractive Lenticule Extraction Surgery. (Pubmed Central) - Mar 23, 2025
These guidelines provide evidence-based recommendations for KLEx in clinical practice, such as for preoperative screening for keratoconus, surgical planning, and management and prevention of complications and infection. The guidelines are expected to minimize the complications and achieve better outcomes.
- |||||||||| Journal: ChatGPT for addressing patient-centred frequently asked questions in glaucoma clinical practice. (Pubmed Central) - Mar 23, 2025
ChatGPT-3.5 responses to FAQs in glaucoma were generally agreeable in terms of coherency, factuality, comprehensiveness, and safety. However, areas of weakness were identified, precluding recommendations for routine use to provide patients with tailored counseling in glaucoma, especially with respect to development of glaucoma and its management.
- |||||||||| Journal: Optimizing deep learning models for glaucoma screening with vision transformers for resource efficiency and the pie augmentation method. (Pubmed Central) - Mar 21, 2025
For both datasets, the AUC values for glaucoma, glaucoma suspects, and no glaucoma were 84.53%, 84.54%, and 91.05%, respectively, which approach the performance of a CNN model that achieved 84.70%, 84.69%, and 93.19%, respectively. Moreover, the incorporation of attention maps from DeiT facilitated the precise localization of clinically significant areas, such as the disc rim and notching, thereby enhancing the overall effectiveness of glaucoma screening.
- |||||||||| Durysta (bimatoprost implant) / AbbVie
Journal: Drug Delivery Systems in Glaucoma- Current Innovations and Future Perspectives. (Pubmed Central) - Mar 20, 2025 In this manuscript, we summarise the limitations of traditional topical anti-glaucoma therapy and study current drug delivery systems to lower IOP, with focus on the only two that have made FDA-approval- Durysta and iDose TR...We also explore the concept of novel nanoparticle-based drug delivery systems, which have the advantage of being highly modifiable and customisable, able to incorporate large amounts of cargo while maintaining a high transfection efficacy, and at a fraction of the cost. Lastly, we propose that nanomedicine, in conjunction with gene therapy, offers a promising solution to the aforementioned challenges of current glaucoma therapy, and can herald a new era of sustained glaucoma treatment.
|